Dr Reddys Laboratories (RDY) EBT (2009 - 2026)

Dr Reddys Laboratories has reported EBT for 18 years, with the latest figure at $58.4 million in Q2 2026.

• On a quarterly basis, EBT fell 73.77% year-over-year to $58.4 million in Q2 2026; TTM through Jun 2026 was $463.8 million, a 48.75% decrease from a year earlier, with the FY2026 full-year figure at $584.0 million, down 35.73% from the prior year.
• EBT was $58.4 million for Q2 2026 at Dr Reddys Laboratories, up from $21.8 million in the prior quarter.
• The five-year high for EBT was $231.6 million in Q1 2025, with the low at $21.8 million in Q1 2026.
• Average EBT over 5 years is $181.9 million, with a median of $214.8 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: EBT jumped 572.29% in 2023, then tumbled 90.6% in 2026.
• Over 5 years, EBT stood at $162.0 million in 2022, then jumped by 35.35% to $219.3 million in 2023, then increased by 1.24% to $222.0 million in 2024, then retreated by 21.95% to $173.3 million in 2025, then tumbled by 66.31% to $58.4 million in 2026.
• The last three EBT figures came in at $58.4 million (Q2 2026), $21.8 million (Q1 2026), and $173.3 million (Q4 2025), per Business Quant data.